Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

abbott laboratories - ABT

ABT

Close Chg Chg %
131.36 -0.54 -0.41%

Closed Market

130.82

-0.54 (0.41%)

Volume: 6.71M

Last Updated:

Mar 28, 2025, 3:59 PM EDT

Trade Now

Company Overview: abbott laboratories - ABT

ABT Key Data

Open

$131.26

 Day Range

130.75 - 133.45

52 Week Range

99.71 - 141.22

 Market Cap

$227.80B

Shares Outstanding

1.73B

 Public Float

1.72B

Beta

0.69

 Rev. Per Employee

N/A

P/E Ratio

16.58

 EPS

$7.70

Yield

176.92%

 Dividend

$0.59

EX-DIVIDEND DATE

Apr 15, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

7.51M

  

ABT Performance

1 Week
 
 3.55%
 
1 Month
 
 -5.21%
 
3 Months
 
 13.77%
 
1 Year
 
 15.10%
 
5 Years
 
 75.46%
 

ABT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 29
Full Ratings ➔

About abbott laboratories - ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

ABT At a Glance

Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Phone 1-224-667-6100 Revenue 41.95B
Industry Medical Specialties Net Income 13.35B
Sector Health Technology 2024 Sales Growth 4.59%
Fiscal Year-end 12 / 2025 Employees 114,000
View SEC Filings

ABT Valuation

P/E Current 16.577
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 14.809
Price to Sales Ratio 4.713
Price to Book Ratio 4.109
Price to Cash Flow Ratio 23.103
Enterprise Value to EBITDA 20.385
Enterprise Value to Sales 4.893
Total Debt to Enterprise Value 0.074

ABT Efficiency

Revenue/Employee 367,982.456
Income Per Employee 117,114.035
Receivables Turnover 6.058
Total Asset Turnover 0.543

ABT Liquidity

Current Ratio 1.671
Quick Ratio 1.233
Cash Ratio 0.563

ABT Profitability

Gross Margin 50.834
Operating Margin 16.331
Pretax Margin 16.718
Net Margin 31.826
Return on Assets 17.269
Return on Equity 30.953
Return on Total Capital 21.213
Return on Invested Capital 23.354

ABT Capital Structure

Total Debt to Total Equity 32.047
Total Debt to Total Capital 24.27
Total Debt to Total Assets 18.762
Long-Term Debt to Equity 28.367
Long-Term Debt to Total Capital 21.483
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Abbott Laboratories - ABT

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
43.08B 43.65B 40.11B 41.95B
Sales Growth
+24.47% +1.34% -8.12% +4.59%
Cost of Goods Sold (COGS) incl D&A
19.86B 21.33B 20.07B 20.63B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.54B 3.27B 3.24B 3.22B
Depreciation
1.49B 1.25B 1.28B 1.34B
Amortization of Intangibles
2.05B 2.01B 1.97B 1.88B
COGS Growth
+15.26% +7.40% -5.90% +2.76%
Gross Income
23.21B 22.32B 20.04B 21.32B
Gross Income Growth
+33.59% -3.84% -10.24% +6.43%
Gross Profit Margin
+53.89% +51.14% +49.96% +50.83%
2021 2022 2023 2024 5-year trend
SG&A Expense
14.01B 13.96B 13.60B 14.47B
Research & Development
2.74B 2.85B 2.72B 2.82B
Other SG&A
11.28B 11.11B 10.88B 11.65B
SGA Growth
+15.95% -0.38% -2.57% +6.41%
Other Operating Expense
- - - -
-
Unusual Expense
523.00M 209.00M 188.00M (2.00M)
EBIT after Unusual Expense
8.68B 8.15B 6.25B 6.85B
Non Operating Income/Expense
(56.00M) 468.00M 1.11B 763.00M
Non-Operating Interest Income
43.00M 183.00M 385.00M 344.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
410.00M 315.00M 698.00M 603.00M
Interest Expense Growth
-42.09% -23.17% +121.59% -13.61%
Gross Interest Expense
410.00M 315.00M 698.00M 603.00M
Interest Capitalized
- - - -
-
Pretax Income
8.21B 8.31B 6.66B 7.01B
Pretax Income Growth
+65.28% +1.16% -19.77% +5.24%
Pretax Margin
+19.06% +19.03% +16.61% +16.72%
Income Tax
1.14B 1.37B 941.00M (6.39B)
Income Tax - Current - Domestic
859.00M 1.31B 528.00M 497.00M
Income Tax - Current - Foreign
790.00M 723.00M 874.00M 1.07B
Income Tax - Deferred - Domestic
(355.00M) (610.00M) (382.00M) (459.00M)
Income Tax - Deferred - Foreign
(154.00M) (49.00M) (79.00M) (7.50B)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(29.00M) (28.00M) (22.00M) (51.00M)
Consolidated Net Income
7.04B 6.91B 5.70B 13.35B
Minority Interest Expense
- - - -
-
Net Income
7.04B 6.91B 5.70B 13.35B
Net Income Growth
+58.28% -1.95% -17.44% +134.19%
Net Margin Growth
+16.35% +15.82% +14.21% +31.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
7.04B 6.91B 5.70B 13.35B
Preferred Dividends
- - - -
-
Net Income Available to Common
7.04B 6.91B 5.70B 13.35B
EPS (Basic)
3.9673 3.939 3.2764 7.673
EPS (Basic) Growth
+57.26% -0.71% -16.82% +134.19%
Basic Shares Outstanding
1.77B 1.75B 1.74B 1.74B
EPS (Diluted)
3.9363 3.9144 3.2596 7.6379
EPS (Diluted) Growth
+57.17% -0.56% -16.73% +134.32%
Diluted Shares Outstanding
1.79B 1.76B 1.75B 1.75B
EBITDA
12.74B 11.63B 9.68B 10.07B
EBITDA Growth
+47.81% -8.71% -16.78% +4.04%
EBITDA Margin
+29.57% +26.64% +24.13% +24.00%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 138.476
Number of Ratings 29 Current Quarters Estimate 1.066
FY Report Date 03 / 2025 Current Year's Estimate 5.153
Last Quarter’s Earnings 1.34 Median PE on CY Estimate N/A
Year Ago Earnings 4.67 Next Fiscal Year Estimate 5.706
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 21 21 23 23
Mean Estimate 1.07 1.25 5.15 5.71
High Estimates 1.09 1.28 5.20 5.90
Low Estimate 0.98 1.14 5.07 5.52
Coefficient of Variance 2.01 2.29 0.57 1.50

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 16
OVERWEIGHT 3 3 5
HOLD 9 8 8
UNDERWEIGHT 1 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Abbott Laboratories - ABT

Date Name Shares Transaction Value
Feb 28, 2025 Philip P. Boudreau EXECUTIVE VICE PRESIDENT 83,783 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Robert B. Ford CHAIRMAN AND CEO; Director 284,956 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Robert B. Ford CHAIRMAN AND CEO; Director 241,706 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 John A. McCoy VICE PRESIDENT 22,719 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mary K. Moreland EXECUTIVE VICE PRESIDENT 39,896 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Mary K. Moreland EXECUTIVE VICE PRESIDENT 101,972 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Lisa D. Earnhardt EXECUTIVE VICE PRESIDENT 69,977 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Lisa D. Earnhardt EXECUTIVE VICE PRESIDENT 80,250 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Louis H Morrone EXECUTIVE VICE PRESIDENT 38,108 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Andrea F. Wainer EXECUTIVE VICE PRESIDENT 45,730 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Louis H Morrone EXECUTIVE VICE PRESIDENT 72,375 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT 61,580 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Daniel Gesua Sive Salvadori EXECUTIVE VICE PRESIDENT 142,231 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 John A. McCoy VICE PRESIDENT 15,040 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Andrea F. Wainer EXECUTIVE VICE PRESIDENT 82,643 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Hubert L. Allen EXECUTIVE VICE PRESIDENT 57,635 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Hubert L. Allen EXECUTIVE VICE PRESIDENT 200,281 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2025 Philip P. Boudreau EXECUTIVE VICE PRESIDENT 61,461 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Robert J. Alpern Director 9,988 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Paola Gonzalez Director 4,125 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Abbott Laboratories in the News

Baby formula maker fills supply gap

While the U.S. is likely months away from seeing more baby formula back on the shelves, one company is looking to help fill the gap.